This Stock Is Up Over 52,700% Since Founding. Should Investors Buy After Its 36% Decline?

Danaher says revenue bottomed and returned to growth in mid-2024, while Q1 non-GAAP earnings rose 9.5% year over year and management guided to more than $5 billion in free cash flow this year. The company also announced a $9.9 billion cash acquisition of Masimo, which is expected to add about $1.5 billion in annual sales and $530 million in EBITDA in 2027. Shares trade at just over 22x estimated earnings versus a 10-year average near 32x, suggesting valuation support despite recent post-pandemic weakness.

Analysis

The setup is less about a classic valuation rerate and more about a multi-year earnings quality reset. Danaher’s core issue was not structural obsolescence but an abnormal demand surge that distorted the base, followed by a normalization period that made organic growth look worse than it really was. That matters because once revenue growth re-accelerates off a depressed comp, operating leverage can reassert quickly, especially in a portfolio model like Danaher’s where integration discipline and pricing power typically show up with a lag.

The Masimo deal is strategically useful beyond the headline revenue addition. It gives Danaher a stronger diagnostics mix at a time when healthcare buyers are favoring sticky, consumable-adjacent workflows over more cyclical instrument demand, and the cash-funded structure avoids a near-term EPS overhang from equity dilution. The second-order read-through is that Danaher is signaling confidence in its balance sheet and acquisition pipeline; that can support a higher floor on the multiple if management can keep turning cash flow into bolt-ons that are immediately accretive.

The market is likely underestimating how much of the discount is sentiment-driven rather than fundamentals-driven. A sub-23x forward multiple is not cheap in isolation, but for a business with mid-to-high single-digit earnings growth, >$5B of free cash flow, and a credible M&A catalyst path, the issue is whether investors will pay for normalization before China stabilizes. The key risk is that China weakness and integration risk could delay the inflection by 2-4 quarters, which would keep the stock range-bound even if the long-term thesis remains intact.

From a trade perspective, this is better expressed as a gradual long than an aggressive momentum chase. The asymmetry improves if post-deal execution is clean and management raises synergy or accretion guidance over the next two earnings prints; if not, the stock can remain a value trap despite better headline growth. The contrarian angle is that the consensus may be overfocusing on the valuation discount and underweighting the fact that Danaher rarely stays cheap once organic growth turns positive and capital deployment regains momentum.

Key Decisions for Investors

• Initiate a 3-6 month long DHR position on pullbacks toward the low end of its recent range; target 15-20% upside if investors start pricing in normalization plus Masimo accretion, with downside limited by cash-flow support.
• For higher conviction, buy DHR Jan-2027 call spreads to capture the multi-quarter integration and growth reacceleration window; this offers cleaner risk/reward than common stock if the market delays re-rating.